Qiagen(QGEN) Qiagen sells the diagnostic tools the labs and doctors use.Qiagen the world's second-largest dutch player, after Roche, in the burgeoning $16 billion field of molecular diagnostics. They acquired Digene for 1.4Billion dollar last year and it looks behind it now as its expected to post 25% growth this year and 24% next year.With purchase of digene it went into testing of human papillomavirus, or HPV. Ever since Merck won approval for its vaccine Gardasil last year, the virus that brings on cervical cancer has brought on a debate over morality and public health as digene was exclusive U.S. seller of tests for high-risk HPV infections.
With purchase of digene Qiagen is also far ahead of its rivals in clinical data, since Digene built up info on hundreds of thousands of women over the years. In an era of heightened federal scrutiny, that could be an advantage.
To broaden its geographical reach, Qiagen will look to expand in Asia. It already has an office in Shenzhen, China; Asia provided 10% of revenue in the latest quarter. Company expects 30% annual growth from that market.
Buy point 19.80
Target 22.50
Stop loss: 18.60
Thursday, June 12, 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment